Esperion Therapeutics Ne (ESPR) Holder Emory University Has Decreased Holding; As Amgen (AMGN) Valuation Declined, Burns J W & Co Lifted Holding by $334,242

January 16, 2018 - By Maria Brooks

Burns J W & Co Inc increased its stake in Amgen (AMGN) by 10.23% based on its latest 2017Q3 regulatory filing with the SEC. Burns J W & Co Inc bought 1,797 shares as the company’s stock declined 9.68% while stock markets rallied. The institutional investor held 19,360 shares of the biological products (no diagnostic substances) company at the end of 2017Q3, valued at $3.61 million, up from 17,563 at the end of the previous reported quarter. Burns J W & Co Inc who had been investing in Amgen for a number of months, seems to be bullish on the $134.37 billion market cap company. The stock increased 0.04% or $0.07 during the last trading session, reaching $185.11. About 2.06 million shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 5.27% since January 16, 2017 and is uptrending. It has underperformed by 11.43% the S&P500.

Emory University decreased its stake in Esperion Therapeutics Inc Ne (ESPR) by 27.35% based on its latest 2017Q3 regulatory filing with the SEC. Emory University sold 12,791 shares as the company’s stock rose 33.24% with the market. The institutional investor held 33,975 shares of the health care company at the end of 2017Q3, valued at $1.70 million, down from 46,766 at the end of the previous reported quarter. Emory University who had been investing in Esperion Therapeutics Inc Ne for a number of months, seems to be less bullish one the $1.87 billion market cap company. The stock decreased 2.83% or $2.07 during the last trading session, reaching $71.19. About 498,816 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since January 16, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on February, 28. They expect $-1.80 earnings per share, down 39.53% or $0.51 from last year’s $-1.29 per share. After $-1.86 actual earnings per share reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -3.23% EPS growth.

Investors sentiment increased to 1.67 in Q3 2017. Its up 0.45, from 1.22 in 2017Q2. It improved, as 11 investors sold ESPR shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported. First Mercantile Tru Company holds 0.02% or 2,714 shares in its portfolio. Quantbot Technology Lp holds 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 721 shares. Massachusetts-based Wellington Grp Llp has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Amundi Pioneer Asset Mngmt Incorporated holds 189,899 shares. Hall Laurie J Trustee has 280 shares. St Johns Mngmt Lc owns 260 shares. Atika Cap Lc stated it has 13,700 shares. 61 are owned by Next Grp. Northern accumulated 577,917 shares. Rhumbline Advisers reported 20,500 shares. Royal Retail Bank Of Canada, Ontario – Canada-based fund reported 3,183 shares. Bank & Trust Of Ny Mellon has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 115,372 shares. State Street Corp owns 1.26 million shares. Macquarie Gru holds 0% or 23,329 shares in its portfolio.

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 12 have Buy rating, 0 Sell and 6 Hold. Therefore 67% are positive. Esperion Therapeutics had 50 analyst reports since July 28, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Monday, June 26. Stifel Nicolaus has “Buy” rating and $6000 target. Credit Suisse downgraded it to “Underperform” rating and $10 target in Wednesday, June 29 report. The company was downgraded on Monday, November 14 by Citigroup. The company was maintained on Wednesday, March 9 by JMP Securities. Needham maintained the shares of ESPR in report on Wednesday, October 18 with “Buy” rating. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Sell” rating by Chardan Capital Markets on Monday, July 27. The rating was maintained by Northland Capital with “Buy” on Wednesday, November 22. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given on Thursday, December 14 by Needham. The firm has “Buy” rating by Citigroup given on Tuesday, February 28. Cowen & Co maintained the stock with “Buy” rating in Wednesday, October 18 report.

Emory University, which manages about $126.35M US Long portfolio, upped its stake in Myovant Sciences Ltd by 28,075 shares to 157,303 shares, valued at $2.43 million in 2017Q3, according to the filing. It also increased its holding in Commscope Hldg Co Inc (NASDAQ:COMM) by 9,152 shares in the quarter, for a total of 50,472 shares, and has risen its stake in Achaogen Inc (NASDAQ:AKAO).

Since October 9, 2017, it had 0 buys, and 2 sales for $553,240 activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.